116 related articles for article (PubMed ID: 38452907)
21. Combination of chemotherapy and immune checkpoint therapy by the immunoconjugates-based nanocomplexes synergistically improves therapeutic efficacy in SCLC.
Tao Z; Kuai X; Wang G; Liu S; Liu K; Zhang H; Xia S; Zhu H
Drug Deliv; 2022 Dec; 29(1):1571-1581. PubMed ID: 35612299
[TBL] [Abstract][Full Text] [Related]
22. Liposomal formulations of Etoposide and Docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines.
Jinturkar KA; Anish C; Kumar MK; Bagchi T; Panda AK; Misra AR
Biomaterials; 2012 Mar; 33(8):2492-507. PubMed ID: 22200537
[TBL] [Abstract][Full Text] [Related]
23. Co-encapsulation of fisetin and cisplatin into liposomes: Stability considerations and in vivo efficacy on lung cancer animal model.
Renault-Mahieux M; Seguin J; Vieillard V; Le DT; Espeau P; Lai-Kuen R; Richard C; Mignet N; Paul M; Andrieux K
Int J Pharm; 2024 Feb; 651():123744. PubMed ID: 38145778
[TBL] [Abstract][Full Text] [Related]
24. PEGylated VRB plus quinacrine cationic liposomes for treating non-small cell lung cancer.
Li XT; Zhou ZY; Jiang Y; He ML; Jia LQ; Zhao L; Cheng L; Jia TZ
J Drug Target; 2015 Apr; 23(3):232-43. PubMed ID: 25417934
[TBL] [Abstract][Full Text] [Related]
25. PEGylated liposomes as delivery systems for Gambogenic acid: Characterization and in vitro/in vivo evaluation.
Tang X; Sun J; Ge T; Zhang K; Gui Q; Zhang S; Chen W
Colloids Surf B Biointerfaces; 2018 Dec; 172():26-36. PubMed ID: 30125771
[TBL] [Abstract][Full Text] [Related]
26. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
[TBL] [Abstract][Full Text] [Related]
27. Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect
Li F; Wang Y; Chen WL; Wang DD; Zhou YJ; You BG; Liu Y; Qu CX; Yang SD; Chen MT; Zhang XN
Theranostics; 2019; 9(20):5886-5898. PubMed ID: 31534526
[TBL] [Abstract][Full Text] [Related]
28. Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small cell lung cancer.
Xie X; Kerrigan JE; Minko T; Garbuzenko O; Lee KC; Scarborough A; Abali EE; Budak-Alpdogan T; Johnson-Farley N; Banerjee D; Scotto KW; Bertino JR
Cancer Biol Ther; 2013 Aug; 14(8):742-51. PubMed ID: 23792570
[TBL] [Abstract][Full Text] [Related]
29. Antitumor Effects of Docetaxel in Truncated Basic Fibroblast Growth Factor- Functionalized Liposomes Delivered by d-α-tocopheryl Polyethylene Glycol 2000 Succinate.
Wen J; Wang Z; Qiu N; Liu H; Shu X; Zhu Z; Bai P; Yang L; Chen L
Curr Pharm Des; 2020; 26(34):4338-4348. PubMed ID: 32324508
[TBL] [Abstract][Full Text] [Related]
30. Which polymer is more suitable for etoposide: A comparison between two kinds of drug loaded polymeric micelles in vitro and in vivo?
Chen L; Tan L; Zhang X; Li J; Qian Z; Xiang M; Wei Y
Int J Pharm; 2015 Nov; 495(1):265-275. PubMed ID: 26325322
[TBL] [Abstract][Full Text] [Related]
31. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
[TBL] [Abstract][Full Text] [Related]
32. PEGylated Liposomes of Meloxicam: Optimization by Quality by Design, in vitro Characterization and Cytotoxicity Evaluation.
Shaji J; Menon I
Pharm Nanotechnol; 2017; 5(2):119-137. PubMed ID: 28462699
[TBL] [Abstract][Full Text] [Related]
33. Tuftsin-Bearing Liposomes Co-Encapsulated with Doxorubicin and Curcumin Efficiently Inhibit EAC Tumor Growth in Mice.
Murugesan K; Srinivasan P; Mahadeva R; Gupta CM; Haq W
Int J Nanomedicine; 2020; 15():10547-10559. PubMed ID: 33414637
[TBL] [Abstract][Full Text] [Related]
34. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity.
Patil Y; Amitay Y; Ohana P; Shmeeda H; Gabizon A
J Control Release; 2016 Mar; 225():87-95. PubMed ID: 26809007
[TBL] [Abstract][Full Text] [Related]
35. Inhalational system for Etoposide liposomes: formulation development and in vitro deposition.
Parmar JJ; Singh DJ; Lohade AA; Hegde DD; Soni PS; Samad A; Menon MD
Indian J Pharm Sci; 2011 Nov; 73(6):656-62. PubMed ID: 23112400
[TBL] [Abstract][Full Text] [Related]
36. Inhalable dry powder prepared from folic acid-conjugated docetaxel liposomes alters pharmacodynamic and pharmacokinetic properties relevant to lung cancer chemotherapy.
Zhu X; Kong Y; Liu Q; Lu Y; Xing H; Lu X; Yang Y; Xu J; Li N; Zhao D; Chen X; Lu Y
Pulm Pharmacol Ther; 2019 Apr; 55():50-61. PubMed ID: 30738974
[TBL] [Abstract][Full Text] [Related]
37. Synergistic Antitumor Efficacy Mediated by Liposomal Co-Delivery of Polymeric Micelles of Vinorelbine and Cisplatin in Non-Small Cell Lung Cancer.
Wang S; Gou J; Wang Y; Tan X; Zhao L; Jin X; Tang X
Int J Nanomedicine; 2021; 16():2357-2372. PubMed ID: 33790554
[TBL] [Abstract][Full Text] [Related]
38. Cisplatin and etoposide as second-line chemotherapy in patients with small cell lung cancer.
Figoli F; Veronesi A; Ardizzoni A; Canobbio L; Bruschi G; Mazza F; Zagonel V; Lo Re G; Rosso R; Monfardini S
Cancer Invest; 1988; 6(1):1-5. PubMed ID: 2835127
[TBL] [Abstract][Full Text] [Related]
39. D-α-tocopherol polyethylene glycol 1000 succinate-modified liposomes with an siRNA corona confer enhanced cellular uptake and targeted delivery of doxorubicin via tumor priming.
Tan X; Fang Y; Ren Y; Li Y; Wu P; Yang X; Liu W
Int J Nanomedicine; 2019; 14():1255-1268. PubMed ID: 30863058
[TBL] [Abstract][Full Text] [Related]
40. A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models.
Chettab K; Fitzsimmons C; Novikov A; Denis M; Phelip C; Mathé D; Choffour PA; Beaumel S; Fourmaux E; Norca P; Kryza D; Evesque A; Jordheim LP; Perrial E; Matera EL; Caroff M; Kerzerho J; Dumontet C
Front Immunol; 2023; 14():1066402. PubMed ID: 37223101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
